Navigation Links
Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
Date:3/1/2013

ROCKVILLE, Md., March 1, 2013 /PRNewswire-USNewswire/ -- Accelovance announces the addition of Ralph Boccia , MD, FACP as the Oncology Medical Director.  The addition of Dr. Boccia is a strong compliment to the oncology strength the Maryland-based CRO that caters to biotech and small/mid pharma Sponsors.  In addition to his responsibilities at Accelovance, Dr. Boccia is a founder and the Medical Director of the Center for Cancer and Blood Disorders.  He also is an active Clinical Associate Professor of Medicine at Georgetown University and consulting Medical Director of the International Oncology Network (ION) Clinical Research Program.

Accelovance offers innovative clinical solutions focused on oncology that accelerate study start up timelines; existing partnerships with leading oncology academic institutions and improved  access to target patient populations that in turn control study budgets.  Such solutions are ideal for Phase I/II and ClinPharm studies where speed, quality and cost-effectiveness are critical to support Sponsor business goals. This model mirrors the highly successful approach utilized by Accelovance with their vaccine and infectious disease programs.

"We are thrilled to have a recognized leader in medical oncology and hematology, Dr. Ralph V. Boccia , join our organization.  His 31 years of practice and clinical research are an asset to the clients we serve as we help define patient populations, study protocols and program approaches," remarked Stephen J. Trevisan , Accelovance President and Chief Executive Officer. "His addition complements our oncology experienced CRO team that has had tremendous growth over the last 12 months in clinical operations, project management and data management."

"It is a unique opportunity to join a forward-thinking, patient-centric clinical services company like Accelovance. This team's commitment to advancing the novel oncology therapies has real value to Sponsors.  We are actively talking to companies with promising technology and it is quite exciting," commented Ralph V. Boccia , MD, FACP.  He is a board-certified Medical Oncologist with specialties in internal medicine and hematology.  Dr. Boccia earned his medical degree at the University of Minnesota and completed training in internal medicine at UCLA-affiliated hospitals.  His hematology, oncology and bone marrow transplant fellowships were completed at the combined UCLA-VA program at the National Cancer Institute (NCI) at the National Institutes of Health in Bethesda, Maryland.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. The Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
gsmith@accelovance.com


'/>"/>
SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
2. Cephasonics Expands Market Presence, Enters Ultrasound Research Market with Large-Channel-Count Modular System Offering Up to 4,096 Channels
3. Hyland Software Expands its Partnership with Nuance Communications to Improve Efficient Care Models at Healthcare Facilities
4. DSI Renal Expands Georgia Presence with Conyers and Kennesaw Dialysis Clinics
5. Cogmedix Expands To Support Laser Based Medical Devices
6. Heraeus Expands Its Venus White Line of Whitening Maintenance and Oral Care Products
7. CryoLife Expands Stock Repurchase Program
8. Modulus Expands Offerings with Patch Design and Manufacturing
9. BioElectronics Expands to the Czech & Slovak Republic
10. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
11. Marken Expands Regulatory And Technical Excellence In Logistics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t have the authority ... gouging for their prescription drugs, according to a new comparison of drug plans ... our behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s ...
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for adventure ... journey that will show that friends are to be gathered but home is always ... Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the University ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... NY (PRWEB) , ... September 19, 2017 , ... ... announced today the addition of strategic marketing leader, Denise Flannery, to its strategic ... Marketing, Brand and Management Consultant, Denise will work with clients across different industries ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to Texas as a part of its national Swirl: A Wine ...
Breaking Medicine News(10 mins):